8-K: Oncolytics Biotech Completes US Redomestication to Nevada

Oncolytics Biotech Inc. has completed its redomestication from Canada to Nevada, aiming for greater operational efficiency and improved access to U.S. capital markets.

Summary

• Oncolytics Biotech Inc. completed a two-step redomestication, first changing its jurisdiction from Alberta, Canada, to British Columbia, Canada, on March 17, 2026.
• The second step, changing jurisdiction from British Columbia, Canada, to Nevada, United States, was completed on March 31, 2026, following shareholder approval on January 15, 2026.
• The company's common stock is now par value $0.001 per share of Oncolytics Nevada, with the company name and Nasdaq ticker symbol (ONCY) remaining unchanged.
• Effective April 1, 2026, the CUSIP number for the common stock is 68237V 103 and the ISIN is US68237V1035.
• The San Diego office will become the company's new headquarters, while the Calgary office will be retained.
• Indemnification and Advancement Agreements were entered into with executive officers and directors, providing for indemnification and expense advancement.
• New Articles of Domestication and Articles of Incorporation were filed with the Nevada Secretary of State, and new Bylaws were adopted, effective March 31, 2026.
• Stockholder rights are now governed by Nevada law and the new corporate documents, which differ from previous Canadian laws and documents.
• The Oncolytics Biotech Inc. 2026 Incentive Award Plan was adopted, effective March 31, 2026, replacing prior plans for new awards.
• The 2026 Plan authorizes 6,500,000 shares, plus any remaining shares from prior plans, forfeited/lapsed awards, and an annual increase (lesser of 6% of outstanding shares or Board-determined number) from January 1, 2027, to January 1, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a strategically positive move for Oncolytics, aligning its corporate structure with its primary investor base and operational focus, which could enhance capital market access. However, the detailed risk factors regarding Nevada corporate law and governance changes introduce some potential concerns for shareholder rights.

Positives

• The transition is expected to bring greater operational efficiency, a streamlined regulatory structure, and improved access to U.S. capital markets.
• Nevada's corporate legal environment presents potential benefits to biotech companies, aligning with the company's focus on operational efficiency.
• The new corporate structure is anticipated to streamline the company's ability to execute on its goals.
• The company no longer qualifies as a foreign private issuer, reflecting its status as a U.S. domestic issuer.

Risks

• Nevada law and the company's governing documents may reduce stockholder rights, limit available remedies, and create uncertainty in corporate disputes.
• Nevada Revised Statutes (NRS) permit limiting individual liability of directors and officers and providing broad indemnification and advancement rights, potentially making it more difficult for stockholders to bring or sustain claims.
• The Bylaws designate specific Nevada state or federal courts as the exclusive forum for certain internal corporate claims and federal claims, which may limit stockholders' ability to choose a favorable judicial forum and could increase costs.
• Nevada's case law interpreting its corporate statutes is less developed than in other states like Delaware, which can make outcomes of corporate disputes less predictable.
• Nevada law and provisions in the Articles of Incorporation and Bylaws could discourage, delay, or prevent a change in control and potentially depress the trading price of common stock.
• The Board is authorized to issue blank check preferred stock with rights, preferences, and limitations as the Board determines.
• Vacancies on the Board may be filled only by a majority vote of the directors then in office.
• The Board has the sole power to adopt, amend, or repeal the Bylaws, while stockholders require a two-thirds vote of outstanding voting power to do so.
• Stockholders may not act by written consent.
• Special meetings of stockholders may be called only by or at the direction of the Board, the chair of the Board, or the chief executive officer.
• Stockholders must comply with advance notice requirements to submit proposals or nominate directors.
• Directors may only be removed by a vote of not less than two-thirds of the outstanding voting power.
• Holders of common stock have no right to cumulative voting.
• All internal actions (as defined in the NRS) must be tried before a judge without a jury.

Future Outlook

The company expects the redomestication to bring greater operational efficiency, a streamlined regulatory structure, and improved access to U.S. capital markets. Management believes Nevada's corporate legal environment presents potential benefits for biotech companies and that the new corporate structure will streamline the ability to execute on goals, although clinical data and regulatory strategy remain key to long-term value creation.

Management Comments

• "Today, most of the Company’s investors, management team, and capital markets activity are U.S.-based. We expect this transition to bring several benefits to the Company and its stockholders, including greater operational efficiency, a streamlined regulatory structure, and improved access to U.S. capital markets." Jared Kelly, Chief Executive Officer.
• "We are encouraged by the potential benefits that Nevada’s corporate legal environment presents to biotech companies, especially given our focus on operational efficiency across the company." Jared Kelly, Chief Executive Officer.
• "As we no longer qualified as a foreign private issuer under applicable U.S. securities laws, it made sense to overhaul our corporate structure and change Oncolytics’ jurisdiction of incorporation to reflect its status as a U.S. domestic issuer." Jared Kelly, Chief Executive Officer.
• "While our clinical data and regulatory strategy will ultimately give us the best opportunity to create long-term value, we believe our new corporate structure will streamline our ability to execute on our goals." Jared Kelly, Chief Executive Officer.

Industry Context

StockSavvy.ai notes that redomestication to the U.S. is a common strategy for Canadian companies with significant U.S. investor bases and operations, particularly in the biotech sector, to simplify regulatory compliance, enhance capital market access, and align corporate governance with U.S. standards. This move positions Oncolytics more directly within the U.S. biotech investment landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: Rights are now governed by Nevada law and new corporate documents, which may reduce stockholder rights, limit remedies, and make changes in control more difficult. Potential for improved access to U.S. capital markets could benefit long-term value.
• Management/Directors: Benefit from new indemnification and advancement agreements, limiting personal liability. The new incentive plan provides a framework for equity compensation.
• Employees: The San Diego office becomes the new headquarters, while the Calgary office is retained. No direct impact on employment terms is mentioned.

Next Steps

• Annual increase in shares for the 2026 Incentive Award Plan beginning January 1, 2027, and ending January 1, 2036.
• Continued advancement of pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers.
• Actively pursuing strategic partnerships to accelerate development and maximize commercial impact.

Key Dates

Recommendation

The redomestication is a strategic move to align the company with its U.S. investor base and potentially improve capital market access, which is generally positive. However, the detailed risk factors regarding changes in corporate governance under Nevada law, which could limit shareholder rights and make changes in control more difficult, introduce a degree of uncertainty. Without new financial or clinical data, a "Hold" recommendation is appropriate as investors assess the long-term implications of these structural changes.

Keywords

Oncolytics Biotech, ONCY, redomestication, Nevada, corporate governance, biotech, capital markets, incentive award plan, pelareorep, SEC filing